4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Soft Tissue Sarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1131 ongoing clinical trials involving Soft Tissue Sarcoma
Of the 1131 trials,309 trials are in Phase I/II
Furthermore, 305 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Soft Tissue Sarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Soft Tissue Sarcoma, an Oncology condition. The largest number of ongoing clinical trials for Soft Tissue Sarcoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Soft Tissue Sarcoma-related drug trials.

National Cancer Institute US: The leading ongoing Soft Tissue Sarcoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Soft Tissue Sarcoma-related ongoing clinical trials.

Memorial Sloan Kettering Cancer Center, Children's Oncology Group, Institut Bergonie, University of Texas MD Anderson Cancer Center, and Sun Yat-sen University are among other notable clinical trial sponsors involved in Soft Tissue Sarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Soft Tissue Sarcoma

Pazopanib hydrochloride (Votrient, Patorma), Eribulin mesylate (E-7389, Halaven), and Trabectedin (Yondelis) are key marketed drugs involving Soft Tissue Sarcoma.

Pazopanib hydrochloride (Votrient, Patorma) is an antineoplastic agent. It functions via Fibroblast Growth Factor Receptor 1 Inhibitor mechanism of action. It is formulated as film coated tablets and tablets for oral administration. It is indicated in adults for the first line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease, and for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS). Votrient is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Pazopanib hydrochloride was first approved in 2009 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Novartis Pharmaceuticals Corp.

Eribulin mesylate (E-7389, Halaven) is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It functions via the Tubulin Inhibitor mechanism of action. It is formulated as a solution for the intravenous route of administration. Halaven is indicated for the treatment of patients with locally advanced or metastatic breast cancer and unresectable or metastatic liposarcoma (leiomyosarcoma) who have received a prior anthracycline-containing regimen. Halaven is also indicated for the treatment of patients with soft tissue sarcoma. Eribulin mesylate was first approved in 2010 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Eisai Inc.